Glucocorticoid has complex effects on osteoblasts. Several of these changes appear to be related to steroid concentration, duration of exposure, or specific effects on growth factor expression or activity within bone. One important bone growth factor, insulin-like growth factor I (IGF-I), is induced in osteoblasts by hormones such as PGE 2 that increase intracellular cAMP levels. In this way, PGE 2 activates transcription factor CCAAT/enhancer-binding protein-␦ (C/EBP␦) and enhances its binding to a specific control element found in exon 1 in the IGF-I gene. Our current studies show that preexposure to glucocorticoid enhanced C/EBP␦ and C/EBP␤ expression by osteoblasts and thereby potentiated IGF-I gene promoter activation in response to PGE 2 . Importantly, this directly contrasts with inhibitory effects on IGF-I expression that result from sustained or pharmacologically high levels of glucocorticoid exposure. Consistent with the stimulatory effect of IGF-I on bone protein synthesis, pretreatment with glucocorticoid sensitized osteoblasts to PGE 2 , and in this context significantly enhanced new collagen and noncollagen protein synthesis. Therefore, pharmacological levels of glucocorticoid may reduce IGF-I expression by osteoblasts and cause osteopenic disease, whereas physiological transient increases in glucocorticoid may permit or amplify the effectiveness of hormones that regulate skeletal tissue integrity. These events appear to converge on the important role of C/EBP␦ and C/EBP␤ on IGF-I expression by osteoblasts. (Endocrinology 141: [127][128][129][130][131][132][133][134][135][136][137] 2000) 
effects on IGF-I expression that result from sustained or pharmacologically high levels of glucocorticoid exposure. Consistent with the stimulatory effect of IGF-I on bone protein synthesis, pretreatment with glucocorticoid sensitized osteoblasts to PGE 2 , and in this context significantly enhanced new collagen and noncollagen protein synthesis. Therefore, pharmacological levels of glucocorticoid may reduce IGF-I expression by osteoblasts and cause osteopenic disease, whereas physiological transient increases in glucocorticoid may permit or amplify the effectiveness of hormones that regulate skeletal tissue integrity. These events appear to converge on the important role of C/EBP␦ and C/EBP␤ on IGF-I expression by osteoblasts. I NSULIN-LIKE growth factor I (IGF-I) is synthesized by many tissues, including bone, where it is a key autocrine and paracrine regulator of osteoblast activity (1) (2) (3) . PTH and PGE 2 , which both increase bone resorption, also stimulate IGF-I synthesis by osteoblasts (4, 5) . The effect of these hormones depends upon their ability to increase intracellular cAMP (6 -8) . Thus, the process of coupled bone remodeling may depend in part on new IGF-I synthesis by osteoblasts to replace previously resorbed bone (9) .
With the availability of information and tools to examine the IGF-I gene promoter, it became possible to assess cis-and trans-acting molecular elements that account for the stimulatory effect of cAMP on IGF-I expression. In mammals the IGF-I gene is greater than 90 kb in length, and its expression originates from either of two transcriptional promoters (10) . In liver, a primary source of circulating IGF-I, both gene promoters are used. In contrast, promoter 1 is the sole or dominant regulatory region of gene transcription in osteoblasts, as it is in other nonhepatic cell types (11) . The cAMP responsive cis-acting region of the IGF-I gene, bp ϩ202 to ϩ209 (5Ј-CGCAATCG-3Ј), was initially termed HS3D by footprint analysis. This sequence occurs within a 5Ј-untranslated region (UTR) of exon 1 (7, 12) and appears to be the most evolutionarily conserved portion of the IGF-I gene, retaining 95% of sequence information between rat and chicken (13) . More recent studies identified C/EBP␦ as the principal cAMP-activated regulator of IGF-I gene transcription in osteoblasts, and that activated C/EBP␦ binds specifically to HS3D to activate IGF-I gene transcription through promoter 1 (14) . In the basal state, osteoblasts constitutively express C/EBP␦, and activation of preexisting C/EBP␦ through a cAMP-dependent protein kinase A (PKA) pathway is sufficient to stimulate IGF-I gene expression (12) .
In other tissues the C/EBP␦ and C/EBP␤ isoforms are thought to be integral components of the acute phase response, where they regulate gene expression during infection, inflammation, and other conditions that engender tissue remodeling (15) (16) (17) (18) (19) (20) (21) (22) (23) . C/EBPs regulate the expression of interleukin-1␤, tumor necrosis factor-␣, and interleukin-6, which in bone can have important effects on osteoclast formation or activation. C/EBPs can therefore influence the expression of cytokines associated with both bone resorption as well as bone formation. Because IGF-I expression is stimulated by PTH and PGE 2 , which also activate bone resorption, IGF-I may have an integral, if not essential, role as a coupling factor in the bone remodeling sequence (9) . Con-sequently, with the identification of C/EBP␦ as the cAMPdependent trans-activator of IGF-I expression in osteoblasts, it may also be relevant to consider C/EBPs as transcriptional coupling factors that coordinate bone remodeling in response to osteotropic hormones.
Cortisol and synthetic glucocorticoids such as dexamethasone (DEX) can have both permissive and suppressive effects on bone remodeling. These effects vary with dose and duration of treatment. For example, exposure to high doses of glucocorticoid or glucocorticoid exposure for extended periods produces clinically significant osteopenia in vivo (24, 25) . In this regard, our studies and those from other laboratories showed that exposure to high doses of glucocorticoid suppresses new IGF-I gene expression by cultured osteoblasts (26 -28) . In contrast, intermittent exposure to glucocorticoid can enhance mineralized nodule formation by cultured osteoblasts and augment the anabolic response to PGs and PTH in cultured bone explants and isolated osteoblasts in vitro (29 -33) . The permissive effect of glucocorticoid on PGactivated osteoblasts also appears to include the IGF-I system, in part through changes in IGF-I expression and specific IGF-binding proteins (33, 34) . However, molecular evidence to reconcile these opposing effects of glucocorticoid on IGF-I expression or activity has not been established. Therefore, our current studies were initiated to examine interactions between glucocorticoid and cAMP on IGF-I gene expression by osteoblasts and to assess whether they converge on changes in C/EBP expression or activity.
Materials and Methods

Cell cultures
Cells were prepared from parietal bones of 22-day-old Sprague Dawley rat fetuses (Charles River Laboratories, Inc., Raleigh, NC) using methods approved by the Yale animal care and use committee. Sutures were eliminated by dissection, and cells were released from parietal bones by five sequential 20-min collagenase digestions, as described previously (35, 36) . Cells released during the last three digestions exhibit biochemical characteristics associated with differentiated osteoblasts, including high levels of PTH receptors and type I collagen synthesis, and a rise in osteocalcin expression in response to 1,25-dihydroxyvitamin D 3 (36, 37) . Histochemical staining demonstrates that approximately 80% of the cells express alkaline phosphatase (McCarthy, T. L., and M. Centrella, unpublished data). By these criteria, differential sensitivity to transforming growth factor-␤, bone morphogenetic protein-2, and various PGs and the ability to form mineralized nodules in vitro (38 -42) , osteoblast-enriched cultures are well distinguished from less differentiated periosteal cells. Cells pooled from the last three digestions were plated at 4800/cm 2 in DMEM containing 20 mm HEPES (pH 7.2), 100 g/ml ascorbic acid, penicillin and streptomycin (Life Technologies, Inc., Grand Island, NY), and 10% FBS (Sigma, St. Louis, MO). All treatments were carried out in serum-free medium. DEX and PGE 2 (Sigma) were dissolved in 95% ethanol. Control treatments included the highest concentration of ethanol (vehicle) present in the treatment reagents. To assess IGF-I messenger RNA (mRNA) stability, cells were pretreated with vehicle or hormones and transcriptionally arrested with the RNA polymerase II inhibitor 5,6-dichloro-␤-d-ribofuranosylbenzimidizole, and the amount of mRNA remaining at various times during the next 24 h was measured (11) .
mRNA analysis
Confluent cultures (ϳ50,000 cells/cm 2 ) were dissolved in 5 m guanidine monothiocyanate, 25 mm trisodium citrate, 0.5% sarcosyl, and 0.1 m 2-mercaptoethanol and extracted with phenol-chloroform-isoamyl alcohol (75:25:1) with 0.2 m sodium acetate (43) . Total RNA was precipitated, ethanol-washed, dried, and resuspended in diethyl pyrocarbonate-treated water. mRNA levels were assessed by ribonuclease (RNase) protection assay. Antisense 32 P-labeled RNA probes were prepared from cloned rat IGF-I, C/EBP␦, and C/EBP␤ constructs. A genomic probe for rat IGF-I exon 3 that contained its upstream intron was used to detect IGF-I pre-mRNA (369 nucleotides) and mature mRNA (143 nucleotides; coding sequence) present in total RNA extracts, as previously described (11) . Expression plasmids encoding C/EBP␦ and C/EBP␤ cloned into pcDNA3 were used to prepare [ 32 P]complementary RNA with a Maxiscript kit (Ambion, Inc., Austin, TX). An 18S ribosomal RNA probe was 32 P labeled with the T7 MEGAshortscript kit (Ambion, Inc.). The probes were gel-purified, and 8 ϫ 10 4 cpm IGF-I, C/EBP␦, or C/EBP␤ [ 32 P]complementary RNA probe were combined with 300 ng 18S probe at low specific activity (1 ϫ 10 3 cpm, due to the high abundance of 18S transcripts) and 5 g total cell RNA in hybridization buffer (80% formamide, 1 mm EDTA, 100 mm sodium citrate, and 300 mm sodium acetate, pH 6.4) at 45 C for 16 h. The samples were digested for 30 min at 37 C with RNase A (0.3 U) and RNase T1 (14 U), and then supplemented with 120 g proteinase K and 0.5% SDS to inactivate RNases (11) . Protected fragments (IGF-I pre-mRNA, 369 nt; IGF-I exon 3, 143 nt; C/EBP␦, 190 nt; C/EBP␤, 260 nt; 18S, 80 nt) were precipitated with 1 vol isopropyl alcohol, collected by centrifugation, resolved on a 5% denaturing polyacrylamide gel, and visualized by autoradiography with Amersham Pharmacia Biotech Hyperfilm (Arlington Heights, IL) and a DuPont Cronex intensifying screen (Wilmington, DE).
Plasmids
A rat IGF-I promoter 1-luciferase fusion construct termed IGF1711b/ Luc, a recombinant construct of IGF1711b/Luc with specific mutations within HS3D (HS3D mutAAA ), a recombinant construct containing four tandem copies of the 19-bp wild-type HS3D sequence (5ЈAGAGCCT-GCGCAATCGAAA-3Ј) (italics indicate C/EBP element) termed 4X HS3D/Luc, and mutated 4X HS3D (4X HS3D mut6 , 5ЈAGAGCCTGTAT-GATCGAAA-3Ј) (underline indicates mutated bases) containing four tandem copies of a nonfunctional HS3D element have all been previously described (7, 12, 14) . HS3D contains the cAMP response element of the rat IGF-I promoter, recently identified as a functional C/EBP-binding sequence (12, 14) . HS3D mut6 fails to bind C/EBP␦ or C/EBP␤ by electrophoretic mobility shift assay, and reporter construct 4X HS3D mut6 is not activated by cAMP (12, 14) . Rat C/EBP␦ and C/EBP␤ complementary DNA clones (provided by Dr. Peter Rotwein, Oregon Health Sciences University), were subcloned into eukaryotic expression vector pSV7d, as previously described (14, 44) . Plasmid pMMTV-Luc, which contains promoter DNA derived from the mouse mammary tumor virus (MMTV) fused upstream of luciferase, was provided by Dr. Ronald Evans (The Salk Institute, La Jolla, CA). A C/EBP␦ dominant negative (C/EBP␦ DN) construct was created by a SacII deletion of its activation domain. All plasmids were propagated in Escherichia coli strain DH5␣ with ampicillin selection and were prepared using a QIAGEN Midiprep Kit (Chatsworth, CA) and the manufacturer's recommended protocol.
Transfections
Promoter/luciferase reporter plasmids were transfected using Lipofectin (Life Technologies, Inc., Gaithersburg, MD) at 0.6 -0.75 g DNA/ 4.8-cm 2 culture well as previously reported (7, 12, 14) . Transfection efficiency was assessed by cotransfection with a vector carrying the ␤-galactosidase gene under the control of the simian virus 40 promoter. Cultures at 50% confluence were rinsed in serum-free DMEM, transfected for 3 h, and then refed with DMEM containing 5% FBS. After 24 -48 h, the cells were rinsed with serum-free medium and treated for the indicated time with vehicle (ethanol diluted 1:1,000 or greater), dexamethasone (1-100 nm), or PGE 2 (0.01-1 m), as indicated. After treatment, cells were rinsed with PBS and lysed in 100 l 25 mm Trisphosphate (pH 7.8), 2 mm dithiothreitol (DTT), 2 mm 1,2-diaminocyclohexane-N,N,NЈ,NЈ-tetraacetic acid, 10% glycerol, and 1% Triton X-100 (cell lysis reagent, Promega Corp.). Lysates were collected, nuclei were pelleted at 12,000 ϫ g for 5 min, and enzyme activity in supernatants was measured with commercial kits for luciferase (Promega Corp.) or ␤-galactosidase (Tropix). Data were corrected for transfection efficiency and protein content (45) .
Nuclear extracts
Osteoblast nuclear extracts were prepared as previously described (7, 12, 14, 46) . Briefly, cell layers were rinsed twice with PBS at 4 C, and all subsequent steps were performed on ice or at 4 C. Cells were harvested, gently pelleted, and lysed in hypotonic buffer (10 mm HEPES, pH 7.4; 1.5 mm MgCl 2 ; 10 mm KCl; and 0.5 mm DTT) with phosphatase inhibitors (1 mm sodium orthovanadate and 10 mm sodium fluoride), protease inhibitors (0.5 mm phenylmethylsulfonylfluoride, 1 g/ml pepstatin A, 2 g/ml leupeptin, and 2 g/ml aprotinin; all from Sigma), and 1% Triton X-100. Nuclei were pelleted, and the cytoplasmic supernatant was collected. Nuclei were resuspended in hypertonic buffer containing 0.42 m NaCl, 0.2 mm Na 2 EDTA, 25% glycerol, and the phosphatase and protease inhibitors indicated above. Soluble nuclear proteins released after 30-min incubation were collected by centrifugation at 12,000 ϫ g for 5 min, and stored in aliquots at Ϫ75 C.
Electrophoretic mobility shift assay (EMSA)
EMSA assays were conducted as previously described (12, 14, 47) . Briefly, radiolabeled double stranded probe was prepared by annealing complementary oligonucleotides, followed by fill-in of single stranded overhangs with deoxy (d)-CTP, dGTP, dTTP, and [␣-
32 P]dATP with the Klenow fragment of DNA polymerase I. Five to 10 g nuclear protein were preincubated for 20 min on ice with 2 g poly(dI:dC) with or without unlabeled specific or nonspecific competitor DNAs in 60 mm KCl, 25 mm HEPES (pH 7.6), 7.5% glycerol, 0.1 mm EDTA, 5 mm DTT, and 0.025% BSA. After the addition of 5 ϫ 10 4 cpm DNA probe (0.1-0.2 ng) for 30 min on ice, samples were applied to a 5% nondenaturing polyacrylamide gel that had been preelectrophoresed for 30 min at 12.5 V/cm at 25 C in 45 mm Tris, 45 mm boric acid, and 1 mm EDTA and then run for 2.5 h at 12.5 V/cm. Dried gels were exposed to x-ray film at Ϫ75 C with an intensifying screen.
The probe containing the C/EBP-binding site that occurs in the IGF-I gene promoter, designated HS3D, used for gel shifts assays was 5Ј-GAGCAGATAGAGCCTGCGCAATCGAAATAAAGTC-3Ј (the C/EBP half-site is underlined). A canonical Sp1 probe (5Ј-ATTCGA-TCGGGCGGGGCGAGC-3Ј; the Sp1 binding motif is underlined) was used as an internal standard for select gel shift studies. Oligonucleotides were produced by Life Technologies, Inc. For supershift analyses, nuclear extracts were incubated with 1 l specific antisera (anti-C/EBP␦ and anti-C/EBP␤ antisera were obtained from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) at 4 C for 30 min before incubation with 32 P-labeled oligonucleotide.
Protein synthesis
To measure protein synthesis rates, cells were pulsed with 12.5 Ci/ml [2,3- 3 H]proline (2.5 Ci/mmol; NEN Life Science Products, Boston, MA) for the last 2 h of culture. The cell layer was lysed by freezethawing, extracted in 0.5% Triton X-100 (Sigma), precipitated with 10% trichloroacetic acid, and chilled, and the acid-precipitated material was collected by centrifugation. Precipitates were acetone extracted, dried, resolubilized in 0.5 n acetic acid, and neutralized with NaOH. [ 3 H]Proline incorporation into collagen (collagenase-digestible) and noncollagen (collagenase-resistant) protein was measured using bacterial collagenase (Worthington Biochemical Corp., Freehold, NJ) free of nonspecific protease activity and is shown as the total amount of [ 3 H]proline incorporation into the cell layer in each culture (2) . The percent collagen synthesis was calculated after correcting for the 5.4-fold greater relative abundance of proline in collagen vs. noncollagen protein.
Reagents PGE 2 , DEX, and cortisol were obtained from Sigma. Antisera to C/EBP␦ and C/EBP␤ were purchased from Santa Cruz Biotechnology, Inc.
Statistical analysis
Data were assessed by one-way ANOVA, with Kruskal-Wallis or Bonferonni methods for post-hoc analysis, using SigmaStat software (SPSS, Inc., Chicago, IL)
Results
Effects of glucocorticoid and PGE 2 on IGF-I mRNA
Our earlier studies revealed that glucocorticoid inhibits IGF-I mRNA and polypeptide expression by osteoblasts and suppresses the stimulatory effect of hormones such as PTH that increase intracellular cAMP (26) . Consistent with this, when osteoblasts were treated for 16 h with 100 nm DEX and then supplemented for 6 h with 0.001-1 m PGE 2 , the stimulatory effect of PGE 2 on IGF-I pre-mRNA expression was significantly reduced; densitometry revealed a nearly 60% suppression of the maximally effective response to PGE 2 (Fig. 1A, compare left and right panels) . In contrast, when cells were pretreated with DEX, and the hormone was removed before stimulation with a moderate dose of PGE 2 (0.1 m), there was a synergistic, nearly 2-fold increase in PGE 2 effectiveness. This effect peaked at 1 nm DEX, a dose that alone had no detectable influence on IGF-I pre-mRNA expression (Fig. 1B) . In agreement with our earlier studies (11), the half-life of IGF-I mRNA in PGE 2 -treated cells was 15 h, without or with previous exposure to DEX, indicating no significant changes in IGF-I mRNA stability.
Requirement for the C/EBP binding sequence in the IGF-I gene
To address mechanisms by which these effects occurred, osteoblasts were transfected with the cAMP-responsive IGF-I promoter/reporter gene construct, IGF1711b/Luc. Cells were pretreated with DEX and then stimulated for 6 h with PGE 2 . At the concentrations tested, DEX alone had no significant effect on IGF-I promoter activity even while it induced a nearly 10-fold increase in reporter gene expression driven by the glucocorticoid response elements in pMMTVLuc (Fig. 2, right panel) . In contrast, a 16-h preexposure to DEX dose-dependently increased the stimulatory effect of PGE 2 on reporter gene expression driven by IGF1711b/Luc by 4-fold (Fig. 2, left panel) . Consistent with its effect in PGE 2 -treated cells, DEX pretreatment enhanced the effect of forskolin on IGF-I promoter activity by 4.5 Ϯ 0.1-fold, whereas the effect of a 6-h cotreatment of DEX and forskolin was essentially equivalent to that of treatment with forskolin alone (data not shown).
We earlier localized the cAMP-responsive element within the IGF-I gene to nucleotides ϩ202 to ϩ209 of exon 1, termed HS3D by footprint analysis, and identified it as a functional binding site for nuclear transcription factor C/EBP (7, 12, 14, 47) . To assess whether this element accounted for the synergy between DEX and PGE 2 on IGF-I expression, we examined changes in reporter gene activity driven by four copies of HS3D fused to a minimal viral promoter in construct 4X HS3D/Luc (14, 47) . Consistent with results from studies with construct IGF1711b/Luc, pretreatment with DEX dose dependently enhanced the stimulatory effect of PGE 2 on 4X HS3D/Luc (Fig. 2, center panel) . In contrast, 6 h of cotreatment with DEX and PGE 2 failed to activate 4X HS3D/Luc more than the effect of PGE 2 alone (Fig. 3, left) . Synergy between preexposure to DEX and subsequent treatment with PGE 2 was undetectable when the HS3D elements were mutated to eliminate C/EBP binding within the synthetic reporter construct, 4X HS3D mut6 (Fig. 3, center) or when the HS3D mu-tation was within the native IGF-I promoter (data not shown). No effect was evident in cells transfected with the promoterless parental construct (Fig. 3, right) . Therefore, DEX cotreatment did not enhance the effect of cAMP on activation of preexisting C/EBP (12, 14) , but the C/EBPbinding site was essential for the synergistic effect of DEX pretreatment. Notably, however, pretreatment with DEX sensitized osteoblasts to previously ineffective (0.01 m) or marginally effective (0.1 m) concentrations of PGE 2 (Fig. 4,  left panel) . Again, no effect on IGF-I promoter activity was evident by cotreatment with DEX and PGE 2 , even with lower amounts of PGE 2 treatment. Sensitization by DEX pretreatment also occurred with the C/EBP-dependent reporter construct 4X HS3D (Fig. 4, right panel) .
Effects on C/EBP binding to DNA
EMSA was then used to determine the effect of DEX pretreatment on C/EBP binding, using 32 P-labeled HS3D oligonucleotide and nuclear extracts from control and hormone-treated osteoblasts. As in previous studies (12, 14) , nuclear extract from untreated cells produced no detectable level of nuclear factor binding, whereas as little as 4 h of treatment with PGE 2 greatly enhanced DNA:protein complex formation. The two prominent complexes that formed were supershifted or eliminated by antiserum to C/EBP␦, whereas antiserum to C/EBP␤ had a lesser effect (Fig. 5A , first four lanes). Nuclear extract from osteoblasts pretreated with DEX formed a low, but detectable, level of complex that was sensitive to anti-C/EBP␦ antiserum (Fig. 5A, lanes 5-7) . Pretreatment with DEX before stimulation with PGE 2 produced a 3-fold greater level of complex compared with that after treatment with PGE 2 alone, similar to the effects of these agents on gene promoter activity (shown above in Figs. 2-4) . Nuclear factor derived from cells treated in this way reacted strongly with antiserum to both C/EBP␦ (supershifted) and C/EBP␤ (reduced binding; Fig. 5A , last three lanes). Complex formation with nuclear extract from cultures cotreated for 6 h with DEX and PGE 2 was not significantly different from that with extract from cells treated with PGE 2 alone (Fig. 5B, center  panel) . Furthermore, DEX and PGE 2 , alone or in a pretreatment protocol, did not affect the binding of transcription factor Sp1 (Fig. 5C, right panel) , suggesting selective effects by both PGE 2 and DEX on nuclear factor function.
Effects on C/EBP␦ and C/EBP␤ expression
Western immunoblots showed that C/EBP␦ and C/EBP␤ were both present in osteoblast-derived nuclear extracts. Earlier studies showed that PGE 2 rapidly increased the amount of C/EBP in nuclear extracts, at least in part through translocation from preexisting cytoplasmic pools (14) . Pretreat- ment with DEX enhanced the levels of both C/EBP␦ and C/EBP␤ in nuclear extracts. This effect appeared maximal by 16 h, as no further accumulation occurred after 32 h of DEX treatment. By densitometry, the combined effect of pretreatment with DEX and subsequent stimulation with PGE 2 was additive. In contrast, cotreatment with both hormones increased the level of each isoform of C/EBP to no more than that caused by stimulation with PGE 2 alone (Fig. 6) .
Based on these results, we examined the effect of DEX on steady-state mRNA levels for C/EBP␦ and C/EBP␤ by RNase protection assay. Pretreatment with DEX caused For pretreatment studies, cells were treated for 16 h with vehicle or 100 nM DEX, and then treated for 6 h with control medium or 1 M PGE 2 . In these instances, DEX was removed before PGE 2 treatment, although similar results occurred when DEX remained in the medium during the short PGE 2 treatment interval. For cotreatment studies, cells were cotreated with DEX and PGE 2 for 6 h. Data are the mean Ϯ SEM and represent two independent experiments, with n ϭ 3/experiment.
FIG. 4.
Sensitizing effect of glucocorticoid on IGF-I gene promoter activity and C/EBP-dependent gene expression. Osteoblast cultures were transfected with either IGF-I promoter construct IGF1711b/Luc or 4X HS3D/Luc. For pretreatment studies, cells were treated for 16 h with vehicle or 100 nM DEX, and then treated for 6 h with control medium or 1 M PGE 2 . In these instances, DEX was removed before PGE 2 treatment, although similar results occurred when DEX remained in the medium during the short PGE 2 treatment interval. For cotreatment studies, cells were cotreated with DEX and PGE 2 for 6 h. Data are the mean Ϯ SEM and represent two independent experiments, with n ϭ 3/experiment. significant and dose-dependent increases in C/EBP␦ and C/EBP␤ mRNAs. Densitometry indicated that at 100 nm DEX, there was a 3-fold increase in C/EBP␦ mRNA and a 4.5-fold increase in C/EBP␤ mRNA (Fig. 7) . Therefore, the synergistic effects of DEX pretreatment and PGE 2 stimulation on IGF-I expression, IGF-I gene promoter activity, and C/EBP-dependent reporter gene expression were consistent with the ability of glucocorticoid to increase new C/EBP␦ and C/EBP␤ expression and their subsequent activation by PGE 2 .
To examine the modulatory effect of DEX on C/EBPdependent IGF-I promoter activation further, we created a C/EBP␦ dominant negative (C/EBP␦ DN) expression construct that lacked the trans-activation domain sequence, but retained dimerization and DNA-binding domains. C/EBP␦ DN effectively suppressed both C/EBP␦-and C/EBP␤-dependent gene expression in COS-7 cells cotransfected with 4X HS3D/Luc (data not shown). With the IGF-I promoterderived reporter construct, C/EBP␦ DN dose dependently suppressed the effect of PGE 2 by up to 94% in both control and DEX-pretreated osteoblasts (Fig. 8) . This effect could not be attributed to nonspecific squelching of reporter gene expression by C/EBP␦ DN, because expression plasmid loading was corrected by complementation with parental vector. Therefore, C/EBPs appear to be essential components for PGE 2 -and DEX-regulated IGF-I promoter activity.
Effects of glucocorticoid and PGE 2 on osteoblast protein synthesis
Finally, our earlier studies showed that an increase in IGF-I expression was responsible in part for the stimulatory effect of PTH or PGE 2 on matrix protein synthesis in intact bone explants (9, 33) . Because preexposure to DEX enhanced the effect of PGE 2 on IGF-I expression, we examined the consequence of these effects on collagen and noncollagen protein synthesis in isolated osteoblasts. By itself, PGE 2 treatment had little effect on collagen synthesis, whereas it produced a small increase in noncollagen protein synthesis (Fig. 9, closed  circles) . In these experiments, pretreatment with DEX alone decreased new collagen synthesis by 70 Ϯ 3% and noncollagen protein synthesis by 30 Ϯ 4%. However, pretreatment with DEX caused a dose-dependent 2-to 2.5-fold increase in new collagen synthesis in PGE 2 -treated cells that was maximal at 0.1 m PGE 2 (Fig. 9, left panel, closed squares) . Similarly, a 3-fold increase in noncollagen protein synthesis occurred under these same conditions (Fig. 9, right panel, closed  squares) .
Discussion
Glucocorticoids are widely used for treatment of asthma, rheumatoid arthritis, inflammatory bowel disease, autoimmune disease, and immunosuppression of organ transplant recipients. Circulating cortisol levels also increase with ag- ing, vigorous exercise, traumatic injury, severe burns, invasive surgery, microgravity, or Cushing's disease (25, 48 -52) . Sustained high levels of glucocorticoids, from pharmacological or endogenous sources, are well known to inhibit skeletal growth and bone remodeling. Importantly, the risk of low trauma fractures increases in nearly one third of all patients receiving long-term glucocorticoid therapy (25) .
IGF-I synthesis by osteoblasts is significantly enhanced by cAMP-inducing factors such as PTH and PGE 2 (4, 5) , and many studies now substantiate that activation of cAMPdependent PKA accounts for the anabolic effects of these hormones on bone (9, 53, 54) . Activation of PKA increases C/EBP␦ activation and binding at ϩ202 to ϩ209 bp within the 5Ј-UTR of exon 1 of the IGF-I gene (7, 12, 14, 47) . This C/EBP-binding element appears evolutionarily conserved among fish, frogs, rats, and humans. Moreover, the entire 5Ј-UTR of exon 1 exhibits a remarkable 95% homology between rats and chickens (12, 13) , suggesting its biological importance for IGF-I gene expression.
Our current studies show that preexposure to glucocorticoid increased the stimulatory effect of PGE 2 on IGF-I synthesis through an increase in new C/EBP␦ and C/EBP␤ expression. The effect of glucocorticoid on C/EBP expression alone was unable to produce large effects on DNA binding or IGF-I promoter activation. Rather, both C/EBP isoforms effectively formed DNA binding complexes and increased gene promoter activity only after treatment with PGE 2 , demonstrating that the higher amount of C/EBPs induced in this way still required activation. A C/EBP␦ DN expression construct virtually eliminated the effects of DEX and PGE 2 , revealing a critical role for C/EBPs on regulation of IGF-I promoter activity. Furthermore, the effectiveness of PGE 2 at activating the IGF-I promoter occurred at a much lower concentration after glucocorticoid pretreatment, suggesting that the normal in vivo spikes in glucocorticoid release that occur throughout the day may have permissive effects on local or circulating osteotropic factors such as PGE 2 and PTH on IGF-I expression by osteoblasts. In contrast, high or sustained levels of glucocorticoid may mask these permissive effects by suppressing new IGF-I expression (26) . Preexposure to glucocorticoid also increased collagen and noncollagen protein synthesis by osteoblasts in response to PGE 2 , consistent with changes previously observed in calvarial organ cultures (33) , demonstrating a physiological consequence from these events.
Interestingly, unlike the IGF-I mRNA studies in Fig. 1 , preexposure to a high dose of DEX increased the effect of PGE 2 on IGF-I promoter/reporter gene expression. This effect persisted regardless of whether DEX remained in the medium during a subsequent, shorter treatment period with PGE 2 . In addition, in transfection studies, low doses of DEX only weakly activated the positive control reporter construct, pMMTV/Luc, whereas it potentiated cAMP-activated endogenous IGF-I gene expression. These findings may reflect different effects by glucocorticoid on native chromatin vs. episomal plasmid DNA, or differences between the half-lives of IGF-I mRNA and the rapidly turning over reporter enzyme luciferase. Moreover, our results suggest that the stimulatory effect of DEX on IGF-I promoter activity depends on an increase in C/EBP expression, which does not itself appear to enhance pMMTV/Luc expression directly. The weaknesses of some assay systems may therefore limit our understanding of results from individual studies, whereas information from several experimental approaches may better represent biological regulatory mechanisms.
C/EBPs regulate the expression of many cytokines and indirectly increase PG expression through an increase in cyclooxygenase-2 expression (55). Activation of C/EBP initiates a biochemical cascade associated with inflammation, wound healing, tissue remodeling, and control of cell proliferation and metabolism. In addition, expression of individual C/EBP isoforms varies with tissue differentiation (21, 56 -60) and can be modulated by the endotoxin lipopolysaccharide, thermal injury, hypoxia, and inflammation itself (15-20, 22, 61, 62) . Acquisition of the adipocyte phenotype by 3T3-L1 fibroblasts parallels a progressive variation in C/EBP isoform expression from C/EBP␦ to C/EBP␤ and finally to C/EBP␣, where C/EBP␣ regulates terminal adipocyte differentiation. This process is initiated by several factors, including glucocorticoid and phosphodiesterase inhibitors that increase cAMP, whereas terminal adipocyte differentiation requires insulin or IGF-I (21, 58 -60) . Similarly, C/EBP␦ is developmentally regulated in fetal lung, and its expression is further induced by cAMP and glucocorticoid (57) . Because of the significant interacting effects that we noted among glucocorticoids, cAMP-inducing agents, and IGF-I on the control of bone cell function, a progression in C/EBP expression and activation also may be important for bone cell differentiation and skeletal integrity (1, 2, 6, 9, 26, 33) . Glucocorticoid-dependent alterations in hormone-induced adenylate cyclase activity or cAMP accumulation can occur in specific tissues or at specific times during development (29, (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) (73) (74) (75) (76) . Whereas glucocorticoid diminishes PGE 2 -induced cAMP in MC3T3-E1 preosteoblasts (70) , it enhances the stimulatory effect of PTH on cAMP synthesis in highly differentiated ROS 17/2.8 osteoblastic cells, in part through an increase in PTH receptor expression (75) . Notably, short term exposure to glucocorticoid in vivo enhances PTH-induced cAMP in perfused bones of rats or dogs, whereas chronic glucocorticoid treatment attenuates PTH activity (29, 63) . Other interacting processes may also be involved. For example, glucocorticoid can reduce protein kinase C activity in rat liver parenchymal cells (77) , and increased levels of cAMP and/or activation of protein kinase A can potentiate glucocorticoid-dependent gene expression by increasing glucocorticoid receptor affinity (78, 79) and consequently its catabolic effects on connective tissue after long term glucocorticoid exposure (80) .
Based on our current results, a working model for the influence of glucocorticoid on IGF-I induction and its actions in osteoblasts is shown in Fig. 10 . At physiological levels, glucocorticoid has a synergistic effect with cAMP-inducing hormones and transiently induces C/EBP␤ and C/EBP␦ expression in osteoblasts. When cAMP rises in response to hormone stimulation, higher endogenous levels of C/EBPs are quickly activated, translocate to the nucleus, and enhance IGF-I promoter activity. In addition, glucocorticoid may modulate PKA, which is stimulatory, and PKC, which suppresses IGF-I expression. Therefore, with transient glucocorticoid pretreatment, PGE 2 or PTH may more effectively activate adenylate cyclase and favor PKA-dependent activation of C/EBP. In contrast, high sustained levels of glucocorticoid may diminish these cooperative events by interfering with C/EBP function and ultimately suppress IGF-I expression. This effect may be C/EBP isoform selective and may result from a physical association between C/EBPs and the glucocorticoid receptor (81, 82; our unpublished observation). However, other findings not presented here indicate no apparent inhibition of C/EBP nuclear translocation by DEX. These and related studies are the subject of ongoing investigations. Finally, transient or sustained exposure to glucocorticoid may influence the biological effects of newly synthesized IGF-I through the downstream signaling events that occur in response to IGF-I itself.
In conclusion, our current studies continue to reveal novel interactions between PKA-activating hormones and glucocorticoids and potential mechanisms for the permissive effects of glucocorticoids on IGF-I expression and protein synthesis by osteoblasts. Future studies will be necessary to define in more detail the complex molecular events that distinguish the permissive and suppressive effects of glucocorticoids on osteoblast function and skeletal integrity. 
